Reply to M.G. McNamara et al and M.S. Copur et al

J Clin Oncol. 2015 Aug 10;33(23):2583-4. doi: 10.1200/JCO.2015.61.8298. Epub 2015 Jun 29.

Authors

Susan M Domchek¹, Bella Kaufman², Michael Friedlander³

Affiliations

¹ Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA Susan.domchek@uphs.upenn.edu.
² Sheba Medical Center, Tel Hashomer, Israel.
³ Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

PMID: 26124483
DOI: 10.1200/JCO.2015.61.8298

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
BRCA1 Protein / genetics*
BRCA2 Protein / genetics*
Female
Germ-Line Mutation*
Humans
Male
Neoplasms / drug therapy*
Neoplasms / genetics*
Phthalazines / therapeutic use*
Piperazines / therapeutic use*

Substances

Antineoplastic Agents
BRCA1 Protein
BRCA2 Protein
Phthalazines
Piperazines